摘要
目的比较膀胱灌注吡柔比星与羟喜树碱预防浅表性膀胱癌术后复发的疗效。方法 50例浅表性膀胱癌术后患者,分为吡柔比星组及羟喜树碱组。羟喜树碱组:膀胱灌注采用羟喜树碱;吡柔比星组:膀胱灌注采用吡柔比星。结果治疗后,两组的淋巴细胞转化率均显著提高(P<0.01)。吡柔比星组与羟喜树碱组的复发率、首次复发时间及淋巴细胞转化率,差异均无统计学意义(P>0.05)。两组患者副作用发生率,差异无统计学意义(P>0.05)。羟喜树碱组治疗费用显著低于吡柔比星组。结论吡柔比星与羟喜树碱预防浅表性膀胱癌术后复发的疗效均可靠、副作用小,但是羟喜树碱可明显节省费用,防止患者因经济承受力不足而中断治疗。
Objective To comparison of curative effect between pirarubicin and hydroxycamptothecine irrigation of bladder prevention of postoperative recurrence about superficial bladder cancer. Methods Fifty cases of superficial bladder cancer divided into THP group and HCPT group. HCPT group： hydroxycamptothecin; THP group： pirarubicin. Results After treatment, the rate of lymphocyte transformation of the two group were significantly increased （P 〈0. 01 ）. The recurrence rate,time and lymphocyte transformation rate to first recurrence of THP group with HCPT group, the difference was not sta- tistically significant （P 〉 0.05）. The incidence of side effects between two groups of patients, the differences were not sta- tistically significant （P 〉 0.05） The cost of treatment of HCPT group was lower than that of THP group. Conclusion Pi- rarubicin and hydroxycamptothecine prevention of superficial bladder cancer recurrence after curative effect, little side ef- fect. However, hydroxy camptothecin, can significantly save costs, prevent patients because of economic affordability and interruption of treatment.
出处
《中国现代医生》
2012年第14期146-147,150,共3页
China Modern Doctor
基金
浙江省医药卫生科学研究基金项目计划(2006B124)
关键词
吡柔比星
羟喜树碱
浅表性膀胱癌
术后复发
淋巴细胞转化率
Pirarubicin
Hydroxycamptothecin
Superficial bladder cancer
Postoperative recurrence
Lymphocyte transfor- mation rate
